Development of gene transfer vectors with regulated, lung specific expression will be a useful tool for studying lung biology and developing gene therapies. In this study we constructed a series of lentiviral vectors with regulatory elements predicted to produce lung specific transgene expression: the surfactant protein C promoter (SPC) for alveolar epithelial type II cell (AECII) expression, the Clara cell 10kd protein (CC10) for Clara cell expression in the airway, and the Jaagskiete sheep retrovirus (JSRV) promoter for expression in both cell types. Transgene expression from the SPC and CC10 vectors was restricted to AECII and Clara cell lines respectively, while expression from the JSRV vector was observed in multiple respiratory and non-respiratory cell types.
Introduction
Gene therapy has been proposed as a treatment for single gene inherited and acute lung disorders. Two components of successful long term gene therapy for lung disorders are the efficient transfer of genes to a self-renewing target cell population and Vectors based on the non-pathogenic human parvovirus, adenoassociated virus (AAV), are also being evaluated for gene delivery in the lung (5) . Recombinant AAV vectors can integrate into cells, but are more often maintained as an episome which is diluted or lost with cell division (5, 6) . Furthermore, their small insert size makes it Page: 4 difficult to produce recombinant vectors with large transcriptional units such as an epithelial specific promoter expressing the cystic fibrosis transmembrane regulator which can be 8kb or more in length.
Non-viral gene transfer systems utilizing liposomes or naked DNA have also been used to transfer genes to the respiratory epithelium (7, 8) . The advantages of these systems are that transgenic cassettes can be transferred without viral sequences, large or multiple genes can be transferred regardless of the proliferative status and cell surface receptor profile of the target cell. However, the overall efficiency of gene transfer is low, genes rarely integrate and the vectors are lost in multiplying cells, and thus this approach is not useful to achieve long-term stable gene therapy.
For long-term gene therapies or biological studies, a vector which can integrate efficiently into the target cell genome is required (9) . Type 'C' retroviruses such as Moloney murine leukemia virus or lentiviruses such as HIV-1 stably integrate into the genome of the target cell. Deletion of the coding sequences for viral gene products renders the gene transfer vectors replication incompetent and makes 6-8kb available for the insertion of desired genes (10) . Lentiviral gene transfer vectors can transduce and integrate into non-dividing cells, however they generally transduce dividing cells more efficiently (11) (12) (13) . (15, 16) or nasal, airway, bronchial and alveolar epithelial cells in vivo (16) (17) (18) (19) (20) . Transduced cells can be detected for long periods of time in vivo, suggesting that these vectors can integrate into either long-lived cells, or respiratory progenitors, which contribute progeny for long periods of time.
A second requirement for gene therapy is the consistent and lineage regulated transgene expression. While constitutive transgene expression may be suitable for gene therapy applications in deficiencies of housekeeping genes, such as lysosomal storage disease or other enzyme deficiencies, it will not be acceptable for other disorders requiring regulation of transgene expression. This is particularly important following the development of leukemias in X-SCID patients receiving hematopoietic cells retrovirally transduced with the common gamma chain cDNA, due to the disregulation of protooncogenes in the genome from the strong retroviral enhancers from the integrated vector (21).
For lineage-restricted transgene expression from lentiviral vectors, a self-inactivating vector design in which the viral promoter and enhancer in the U3 region of the 3' long terminal repeat (LTR) are removed from the vector plasmid can be used. During integration, the U3 region of the 3'LTR is copied to the 5'LTR, thereby resulting in the elimination of the 5' viral promoter in the integrated provirus (14, 22) . The transgene can be expressed from an internal lineage specific or regulated promoter/regulatory elements. Lentiviral vectors have been used for regulated transgene expression in a variety of lineages such as B lymphocytes (23) , T lymphocytes (24, 25) or erythrocytes (26, 27) , however they have not been described for respiratory cell types.
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In these studies we describe the development and evaluation of a series of lentiviral vectors in which an EGFP marker transgene is expressed from promoters and regulatory elements predicted to provide airway and/or alveolar epithelial specific expression. The cellular promoters evaluated in this study are from the surfactant protein C (SPC) (28) or the Clara cell 10 kd secretory protein (CC10) (29) genes to provide alveolar epithelial type II (AECII) or for Clara cell restricted expression respectively. The promoter from the Jaagskiete sheep retrovirus (JSRV) which is predicted to express in both AECII and Clara cells (30) , was also evaluated. The lineage profile of transgene expression from lentivectors with each of these promoters was evaluated in cell lines in vitro and in lungs following in vivo delivery of viral supernatant to mice. This study describes the development of lentivirus vectors with respiratory epithelial specific transgene expression which will facilitate the development of lung gene therapies, and the study of lung development and biology.
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Materials and Methods

Vector construction and supernatant production
The lentiviral vector backbone used in this study was the pCCL self-inactivating vector kindly provided by Dr. Luigi Naldini (CellGenesys) (14) . In this backbone, the viral enhancers and TATA box in the U3 promoter region of the 3'LTR have been deleted.
This results in a crippling of the promoter in the integrated provirus, as the U3 region of the 3'LTR is copied to the 5'LTR during integration.
The basic vector backbone, CCL-X-EGFP, contains a multicloning site (X) upstream of the EGFP reporter gene into which the test promoters could be inserted. This vector backbone also served as a 'no-promoter' negative control. The human SPC promoter was investigated for alveolar type II epithelial specific expression (28) . The rat Clara cell 10kd protein (CC10) promoter was evaluated for airway specific expression in Clara cells (29) . The CC10 and SPC promoters were from Dr. Jeffrey Whitsett (Cincinnati Children's Hospital Medical Center). For expression in both AECII and Clara cells we evaluated the promoter from the U3 region of the JSRV from Dr. Hung Fan (University of California, Irvine) was evaluated. The lentivector with the constitutive promoter from the retroviral MND vector LTR (31) promoter/enhancer was provided by Dr. Donald B.
Kohn (Childrens Hospital Los Angeles) and used as positive control vectors in these studies.
VSV-G pseudotyped lentiviral supernatants were produced by triple transfection of the human embryonic kidney 293T cell line as previously described (23) . In brief, 5X10 
In vivo delivery of lentivirus supernatant
To evaluate the lineage profile of transgene expression in primary tissues, mice were injected with lentiviral supernatant either intravenously or intra-tracheally. Intravenous administration was performed as described (32) . In brief, each day 0 neonatal C57B6J pup received 1x10 8 iu diluted to 50µl with sterile preservative-free saline and 8µg/ml polybrene delivered via the facial vein. The pups weighed from 1.3-1.8 grams at the time of injection, resulting in a vector dose of 5.5-7.7x10 7 iu/gram. Following the injections, the pups were returned to their nest, nursed and weaned following standard protocols.
For intra-tracheal delivery of lentivirus/KGF mixture, anesthesia was induced with 5% isofluorane and maintained with 2.5% isofluorane in 6-8 week-old athymic nude mice (Harlan, Indianapolis, IN). The neck was extended and cleaned with a chlorhexidine solution. A small midline incision was made with a sterile scalpel to expose the trachea.
A total volume of 50 µl containing 1x10 8 vector particles (suspended in 0.9% saline with 5mg/kg rhKGF) was injected into the trachea using a ½ cc Insulin syringe with 28Ga
needle (Becton-Dickson). Control mice received intratracheal delivery of 50ul saline mixed with 5mg/kg rhKGF. After injection, the wound was treated with 1-2 drops of Page: 11 bupivicane (as a local anesthetic) and closed with a tissue adhesive. The mice were given antibiotics (Maxim-200µg/ml in sterile water) for 1 month and ketoprofen subcutaneously on the day of surgery, and the day following surgery. The mice were sacrificed at 1-6 weeks post-injection for EGFP expression analysis.
Immunofluorescence staining of tissue sections
Frozen lungs were sectioned at 5µm on a CM1900 cryostat (Leica, Bannockburn, IL) and placed on a Plus glass slide (Fisher Scientific, Tustin, CA). Dried sections were fixed with pre-cooled (-20°C) 100% acetone for 10 min at room temperature. The sections were stained to localize AECII and Clara cells within the tissues and evaluate which lineages were expressing EGFP. Sections were blocked with 5% normal donkey serum containing 1% BSA, 0.1% triton X-100 and 0.05% tween 20 in PBS for 2 hours at room temperature before applying primary antibody. Samples to be stained with antibodies directed against CD45 were blocked with the same buffer, without the addition of Triton X-100. Negative controls were used with every experiment, and included negative control mice treated with PBS, as well as sections from each control and experimental animal incubated with buffer without a primary antibody. All samples were visualized through a fluorescent compound microscope (Leica DMRXA) and images were captured with a digital camera (Spectra cube), and acquired using EasyFISH software (Applied Spectral Imaging, Preston, UK).
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Analysis for proviral DNA sequences DNA was extracted using the Puregene DNA Isolation kit (Gentra Systems, Minneapolis, MN) using the manufacturer's recommended protocols. Standard PCR analysis for proviral EGFP and β-actin genomic control DNA sequences was performed on transduced cell lines and tissues from in vivo supernatant treated animals to confirm that they contained proviral sequences as described (33) . The average vector copy number was determined in available DNA samples by quantitative real time polymerase chain reaction (PCR) analysis, by comparison to serial logarithmic dilutions of genomic DNA from a Jurkat clone carrying a single copy per cell as described (31) .
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Results
Construction and titering of lentiviral vectors with tissue specific promoters
A series of lentiviral vectors were constructed in which the EGFP transgene was expressed from either an internal SPC, CC10 or JSRV promoter. Transgene expression from these vectors was compared to a positive control vector with the constitutive promoter from the U3 region of the MND retrovirus LTR (31) . A no promoter control served as a negative control for cell line experiments. Schematic diagrams of each vector are shown in Figure 1 . The vectors were packaged into recombinant lentiviral particles with the VSV-G protein as the envelope to transduce a wide variety of cell types. Since there was not a single cell line which would express all of the promoters evaluated in this study, titers were calculated following transduction of each vector into a cell line known to express it as described above.
Evaluation of EGFP transgene expression in cell lines
In the first set of experiments, transgene expression was evaluated from each of the The relative EGFP expression from the CCL-SPC-EGFP vector in all non-respiratory epithelial cell lines was less than 0.10 ( Figure 3B ). Statistical analysis demonstrated that there was a significant difference between EGFP expression in AECII cell lines MLE-12
and MLE-15 compared to all non-respiratory cell lines (all p<0.002, 2-tailed T-test).
Collectively, these data demonstrate that proviral EGFP expression from the SPC promoter is highly specific to SPC positive AECII cell lines.
In contrast to the expression from the SPC and CC10 lentivectors, moderate to high To confirm that a lack of transgene expression from a promoter was not due to a lack of proviral transduction in these experiments, all samples were evaluated by PCR Page: 17 analysis for proviral EGFP sequences. The data from a representative PCR analysis is shown in Figure 4 , demonstrating the presence of proviral EGFP sequences in all transduced cells lines. This confirms that a lack of EGFP expression observed in nonrespiratory cell lines from the SPC and CC10 promoters was not due to a lack of gene transfer, but rather due to differences in the regulation of transgene expression in different cell types.
EGFP expression in respiratory tissues following in vivo administration of CC10-EGFP vector
To evaluate transgene expression from the CC10 and SPC lentivectors in primary respiratory epithelium, lentiviral supernatants were injected directly into the tracheas of recipient athymic nude mice. Nude mice were used in these studies to facilitate cleaning the neck region for surgery and visualizing the trachea for injection. In preliminary studies, mice were administered lentiviral supernatant intra-tracheally without KGF treatment, however, no transduction was observed (data not shown). While lentiviral vectors can transduce non-dividing cell types, higher efficiency of transduction has been demonstrated in several cell types, with the induction of cell cycling (11) (12) (13) . In all intratracheal delivery experiments presented here the mice were treated with KGF prior to, and at the time of, viral administration to increase Clara cell (34) and AECII (35) Figure 5D ). These studies demonstrate that lentiviral vectors carrying the CC10 promoter direct transgene expression to both AECII in the alveolar tissue and Clara cells in the airway tissue in vivo.
EGFP expression in respiratory tissues following in vivo administration of SPC-EGFP vector
In recipients of intra-tracheal CCL-SPC-EGFP vector supernatant, cells immunoreactive for both EGFP and pro-SPC were observed in the alveolar tissue at all time points evaluated. The morphology, localization and pro-SPC punctate staining pattern of these double EGFP and pro-SPC positive cells were consistent with AECII. In the seven recipients of the CCL-CC10-EGFP supernatant, proviral sequences were detected in all livers, and the majority of spleens, hearts and kidneys from neonatal recipients (Table 2) . Subsequently, the level of transduction was evaluated by, quantitative real-time PCR analysis on available samples. The proviral copy number in the tissues ranges from 0.060-0.175 copies per cell on average in the liver (the highest).
Lower copy numbers were observed in the heart (range: 0.00025-0.09), spleen (range:
0.027-0.030), and kidneys (range: 0.00002-0.00006). The level of gene transfer observed in these studies is in accordance with the levels of transduction observed in other studies of lentiviral supernatant injection into neonates (32) . All of the liver, heart, spleen and kidney tissues that were positive for proviral sequences in either assay were subject to EGFP immunofluorescence microscopy analysis. Two well-spaced tissue sections were evaluated for each tissue, and EGFP expression was not detected in any of the sections analyzed (data not shown). Given copy numbers of up to 0.175
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(corresponding to up to 17.5% of cells carrying a single proviral genome), this data supports the in vitro cell line data demonstrating that transgene expression is not observed in several non-respiratory tissues from the CCL-CC10-EGFP vector.
In the four intravenous recipients of the CCL-SPC-EGFP vector, all DNA samples from the spleen and liver, three of the four heart, and one of four kidney samples were positive for proviral EGFP sequences ( Table 2 ). Quantitative PCR analysis was performed on available DNA samples. Average proviral copy numbers ranged between 0.003 to 0.09 for the heart (3 samples), 0.01 to 0.025 for the spleen (3 samples) and 0.03 for the kidney (1 sample). Two tissue sections from all provirus positive tissues were evaluated for EGFP expression. All tissue sections were negative for EGFP expression by immunofluorescence analysis (data not shown). These data demonstrated a variation in the level of gene transfer to non-respiratory tissues using the neonatal intravenous approach. However, the lack of transgene expression observed in any non-respiratory tissue supports the in vitro data indicating that the CCL-SPC-EGFP lentivector is not expressed in non-respiratory tissues. Collectively, the in vitro and in vivo data presented above indicates that these lentivectors produce regulated, respiratory specific transgene expression.
Discussion
Lineage regulated transgene expression will be necessary for effective, long-term gene 
